Ann: Race appoints Dr Michelle Rashford Chief Medical Officer, page-33

Race Oncology has been incredibly fortunate to attract someone of Michelle's caliber, and I believe that this is just the beginning of many great things to come.
Michelle must have thoroughly researched Race and Zantrene before accepting the position.
To me, this also suggests that Race is initially heading down the partnership route, which is not a bad thing if we aim to achieve good buyout premiums.
Buyouts after Phase 2 results are generally significantly higher than those that occur before Phase 2.
Currently, what we require is the approval from the governance committee for the new formulation before commencing the Phase 2 cardioprotection trial.
In contrast to EMD AML, the clinical acceptance of BC cardioprotection should be highly favorable, and there is even a possibility of obtaining results by the second half of next year.
I am utilizing this opportunity to live on a budget and continue purchasing RAC, as acquiring RAC shares after receiving the clinical results would be way way more expensive.

Some supportive results- including @Mason14 summary